American Sales Co. v. AstraZeneca LP, 842 F.3d 34

Background

AstraZeneca, holder of Nexium patents, settled paragraph IV suits with Ranbaxy, Teva, and Dr. Reddy’s; Ranbaxy was first filer and its settlement included a no-authorized-generic clause plus supply/distribution side deals.
Plaintiffs (direct purchasers, end-payors, and retailers) sued alleging the settlements—especially AstraZeneca’s payments/benefits to Ranbaxy and Teva—were unlawful reverse payments in violation of antitrust law.
After summary judgment the district court allowed the Teva-based theory and overarching-conspiracy theory to proceed but limited other causation theories; at trial the court later granted JMOL for defendants on overarching conspiracy and on causation theories requiring patent invalidity.
The jury found AstraZeneca made a “large and unjustified payment” and that the settlement was unreasonably anticompetitive (liability), but found plaintiffs failed to prove a but‑for earlier launch date (no antitrust injury/damages).
Plaintiffs appealed, challenging evidentiary rulings (notably exclusion of an event‑study), the JMOL on conspiracy, the verdict form/instructions, and the district court’s summary‑judgment narrowing of causation theories.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Admissibility of McGuire’s Event‑Study and related testimony	Excluding the event study and further McGuire testimony prejudiced plaintiffs and deprived the jury of key but‑for evidence	Event‑study lacked fit under Daubert; additional McGuire testimony would be cumulative and unfair	Exclusion affirmed—trial court did not abuse discretion under Daubert and exclusion was not prejudicial
JMOL on overarching (hub‑and‑spoke) conspiracy	Parallel contingent‑launch provisions and conduct sufficed to show an overarching horizontal conspiracy	Evidence showed independent, self‑interested vertical deals with AstraZeneca (a rimless wheel); no plus‑factors to infer agreement among generics	JMOL for defendants affirmed—insufficient evidence of an agreement among generics to support overarching conspiracy
Verdict form & jury instructions (Question 4: causation/injury)	Question 4 was duplicative/confusing/subjective and imposed too stringent causation standard	Form properly separated liability (antitrust violation) from antitrust injury (but‑for earlier entry); court clarified instructions were objective	Affirmed—Q3 (violation) and Q4 (injury/causation) were distinct; plaintiffs forfeited many objections and no plain error shown
Summary judgment trimming of causation theories (and related exclusion of evidence)	District court improperly foreclosed multiple causal mechanisms, so trial was deprived of necessary proof of but‑for entry and injury	Any summary‑judgment error was harmless: (1) JMOL on patent‑invalidity theories mooted at‑risk/Teva victory theories; (2) jury’s no on causation and admitted evidence rendered any error harmless	Affirmed—any summary‑judgment limits were rendered harmless by trial developments, JMOL on patent invalidity, and the jury verdict

Key Cases Cited

FTC v. Actavis, 133 S.Ct. 2223 (Supreme Court 2013) (reverse payments may be unlawful under the rule of reason)
In re Loestrin 24 Fe Antitrust Litig., 814 F.3d 538 (1st Cir. 2016) (non‑monetary settlement benefits can constitute reverse payments)
Daubert v. Merrell Dow Pharm., 509 U.S. 579 (1993) (trial court gatekeeping standard for expert admissibility)
General Elec. Co. v. Joiner, 522 U.S. 136 (1997) (abuse‑of‑discretion standard for evidentiary rulings on expert testimony)
Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (conscious parallelism insufficient; need plus‑factors to infer agreement)
Brunswick Corp. v. Pueblo Bowl‑O‑Mat, 429 U.S. 477 (1977) (definition of antitrust injury)
Atlantic Richfield Co. v. USA Petroleum Co., 495 U.S. 328 (1990) (proof of violation and proof of antitrust injury are distinct requirements)
Samaan v. St. Joseph Hosp., 670 F.3d 21 (1st Cir. 2012) (Daubert standard application in First Circuit)